Inhaled insulin

Advanced Drug Delivery Reviews

Volumn 35, Issue 2-3, 1999, Pages 235-247

  Patton, John S ^a   Bukar, Julie ^a   Nagarajan, Sudha ^a  

^a NEKTAR THERAPEUTICS   (United States)

Author keywords

Absorption; Aerosol; Device; Human; Inhalation; Insulin; Lung; Particle size; Pulmonary; Reproducibility; Safety

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PATIENT SATISFACTION; PRIORITY JOURNAL; RELIABILITY; REPRODUCIBILITY; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032969699     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(98)00074-X     Document Type: Review

References (63)

1. American Diabetes Association, Diabetes 1996: Vital Statistics, 1996.
2. R.C. Bonney, Scrip Reports: Diabetes Towards 2000, PJP Publications, Surrey, UK, 1995.
3. Libman I., Songer T., LaPorte R. How many people in the U.S. have IDDM? Diabetes Care. 16:1993;841-842.
4. K.G.M.M. Alberti, P. Zimmet, R.A. DeFronzo, H. Keen, International Textbook of Diabetes Mellitus, Wiley, Chichester, 1997, pp. 136, 635, 1767.
5. National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Diabetes in America, NIH Publication No. 95-1468, Bethesda, 1995.
6. M. Ellenberg, H. Rifkin, Diabetes Mellitus, 3rd ed., Medical Examination Publishing, Amsterdam, 1983, pp. 119-150.
7. Dimitriadis G.D., Gerish J.E. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care. 6:1983;374-377.
8. Patrick A.W., Collier A., Mathews D.M., Macintyre C.C.A., Clark B.F. The importance of the time interval between insulin injection and breakfast in determining postprandial glycemic control: a comparison between human and porcine insulin. Diabetic Med. 5:1988;32-35.
9. Holleman F., Hoekstra J.B.L. Insulin Lispro. New Engl. J. Med. 337:1997;176-183.
10. Wilde M.I., McTavish D. Insulin Lispro. A review of its pharmacological properties and therapeutic use in the management of diabetes mellitus. Drugs. 54:1997;597-614.
11. Burge M.R., Castillo K.R., Schade D.S. Meal composition is a determinant of lispro-induced hypoglycemia in IDDM. Diabetes Care. 20:1997;152-155.
12. Hilsted J., Madsbad S., Hvidberg A., Rasmussen M.H., Krarup T., Ipsen H., Hansen B., Pedersen M., Djurup R., Oxenboll B. Intranasal insulin therapy: the clinical realities. Diabetologia. 38:1995;680-684.
13. Salzman R., Manson J.E., Griffing G.T., Kimmerle R., Ruderman N., Phil D., McCall A., Stoltz E.I., Mullin C., Small D., Armstrong J., Melby J.C. Intranasal aerosolized insulin: mixed-meal studies and long-term use in type I diabetes. New Engl. J. Med. 312:1985;1078-1084.
14. Moses A.C., Gordon G.S., Carey M.C., Flier J.S. Insulin administered intranasally as an insulin-bile salt aerosol: effectiveness and reproducibility in normal and diabetic subjects. Diabetes. 32:1983;1041-1047.
15. Jacobs M.A.J.M., Schreuder R.H., Jap-A-Joe K., Nauta J.J., Andersen P.M., Heine R.J. The pharmacodynamics and activity of intranasally administered insulin in healthy male volunteers. Diabetes. 42:1993;1649-1655.
16. Heinemann L., Traut T., Heise T. Time-action profile of inhaled insulin. ETIC Med. 14:1997;63-72.
17. Patton J.S., Platz R.M. Routes of delivery: case studies (2); pulmonary delivery of peptides and proteins for systemic action. Adv. Drug Deliv. Rev. 8:1992;179-196.
18. Patton J.S., Trinchero P., Platz R.M. Bioavailability of pulmonary delivered peptides and proteins: interferon alpha, calcitonins and parathyroid hormones. J. Control. Release. 28:1994;79-85.
19. Niven R.W. Delivery of biotherapeutics by inhalation aerosol. Crit. Rev. Ther. Drug Carrier Syst. 12:1995;151-231.
20. Gansslen M. Uber Inhalation von Insulin. Klin. Wochenschr. 4:1925;71.
21. Wigley F.M., Londono J.H., Wood S.H., Shipp J.C., Waldman R.H. Insulin across respiratory mucosa by aerosol delivery. Diabetes. 20:1971;552-556.
22. Elliott R.B., Edgar B.W., Pilcher C.C., Quested C., McMaster J. Parenteral absorption of insulin from the lung in diabetic children. Aust. Paediatr. J. 23:1987;293-297.
23. Köhler D., Schluter K.J., Kerp L., Matthys H. Nicht radioaktives Verfahren zur Messung der Lungenpermeabilitat: Inhalation von Insulin. Atemwegs.- Lungenkr. 13:1987;230-232.
24. Laube B.L., Georgopoulus A., Adams G.K. Aerosolized insulin delivered through the lungs is effective in normalizing plasma glucose levels in non-insulin dependent diabetic subjects (NIDD). J. Biopharm. Sci. 3:1992;163-169.
25. Laube B.L., Georgopoulus A., Adams G.K. Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients. J. Am. Med. Assoc. 269:1993;2106-2107.
26. Jendle J.H., Karlberg B.E. Intrapulmonary administration of insulin to healthy volunteers. J. Intern. Med. 240:1996;93-98.
27. Jendle J.H., Karlberg B.E. Effects of intrapulmonary insulin in patients with non-insulin-dependent diabetes. Scand. J. Clin. Lab. Invest. 56:1996;555-561.
28. Klaus J.S., Kohler D., Enzmann F., Kerp L. Pulmonary administration of human insulin in volunteers and type I diabetics (abstract). Diabetes. 33:1984;75.
29. Ward E., McElduff A., Lee R.-Y., Okikawa J., Lloyd P., Schuster J., Cipolla D., Gonda I., Mather L., Farr S. Pharmacodynamics of pulmonary delivered insulin in healthy fasted volunteers (abstract). J. Aerosol Med. 10:1997;3.
30. Farr S., McElduff A., Ward E., Okikawa J., Lloyd P., Schuster J., Mather L., Gonda I. The mode of inhalation influences the pharmacokinetics and pharmacodynamics of pulmonary delivered insulin in healthy fasted volunteers (abstract 1382). Pharm. Res. 14(Suppl.):1997;S136.
31. B.L. Laube, G.W. Benedict, A.S. Dobs, Time to peak insulin level, relative bioavailability and effect of deposition of nebulized insulin in patients with non-insulin dependent diabetes mellitus, J. Aerosol Med. (in press).
32. Guerra S.M.O., Kitabchi A.E. Comparison of the effectiveness of various routes of insulin injection: insulin levels and glucose response in normal subjects. J. Clin. Endocrinol. Metab. 42:1976;869-874.
33. Berger M., Cuppers H.J., Hegner H., Jorgens V., Berchtold P. Absorption kinetics and biologic effects of subcutaneously injected insulin preparations. Diabetes Care. 5:1982;77-91.
34. Murat A., Slama G. Influence of concentration on the kinetics of SC-infused insulin. Comparison between square-wave SC infusion and bolus SC injection. Metabolism. 34:1985;120-123.
35. Edsberg B., Herly D., Hildebrandt P., Kuhl C. Insulin bolus given by sprinkler needle: effect on absorption and glycemic response to a meal. Br. Med. J. 294:1987;1373-1376.
36. Ziel F.H., Davidson M.B., Harris M.D., Rosenberg C.S. The variability in regular insulin action is more dependent on changes in tissue sensitivity than absorption. Clin. Res. 35:1987;160-166.
37. Galloway J.A., Spradlin C.T., Nelson R.L., Wentworth S.M., Davidson J.A., Swarner J.L. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care. 3:1981;366-376.
38. Roy B., Chou M.L., Field J.B. Time-action characteristics of regular and NPH insulin in insulin-treated diabetics. J. Clin. Endocrinol. Metab. 50:1980;475-479.
39. Phase II Study Group, Treatment of type I diabetes mellitus with inhaled human insulin: a 3-month, multicenter trial (abstract 236), Diabetes 47 (Suppl. 1) (1998) A61.
40. Phase II Study Group, Treatment of type I diabetes mellitus with inhaled human insulin: a 3-month, multicenter trial (abstract 237), Diabetes 47 (Suppl. 1) (1998) A61.
41. Phase II Study Group, Pharmacological reproducibility of inhaled human insulin pre-meal dosing in patients with type 2 diabetes mellitus (NIDDM) (abstract 388), Diabetes 47 (Suppl. 1) (1998) A99.
42. Phase II Study Group, Add-on therapy with inhaled human insulin in type 2 diabetic patients failing oral agents: preliminary results of a multicenter trial (abstract), Eur. Diabetes Assoc. (in press).
43. Farr S., McElduff A., Ward E., Okumu F., Mather L., Gonda I., Rubsamen R. A comparison of the pharmacokinetics and pharmacodynamics of inhaled insulin administered as different strength solutions to healthy volunteers (abstract 235). Diabetes. 47(Suppl. 1):1998;A61.
44. McElduff A., Farr S., Ward E., Okumu F., Mather L., Gonda I., Rubsamen R., DiMarchi R., Wolff R. Comparison of the pharmacokinetics and pharmacodynamics of subcutaneous and inhaled lispro in healthy fasted volunteers (abstract 413). Diabetes. 47(Suppl. 1):1998;A105.
45. J.S. Patton, S. Nagarajan, A.R. Clark, Pulmonary absorption and metabolism of peptides and proteins, in: R.S. Dalby, P.R. Byron, S.J. Farr (Eds.), Respiratory Drug Delivery VI, Interpharm Press, Buffalo Grove, 1998, pp. 17-24.
46. Patton J.S. Review: mechanisms of macromolecule absorption by the lungs. Adv. Drug Deliv. Rev. 19:1996;3-36.
47. S.P. Neuman, P.H. Hirst, G.R. Pitcairn, A.R. Clark, Understanding regional lung deposition data in gamma scintigraphy, in: R.S. Dalby, P.R. Byron, S.J. Farr (Eds.), Respiratory Drug Delivery VI, Interpharm Press, Buffalo Grove, 1998, pp. 9-15.
48. Okumura K., Iwakawa S., Tsuguchika Y., Toshimitsu S., Komada F. Intratracheal delivery of insulin absorption from solution and aerosol by rat lung. Int. J. Pharm. 88:1992;63-73.
49. Yamamoto A., Umemori S., Muranishi S. Absorption enhancement of intrapulmonary administered insulin by various absorption enhancers and protease inhibitors in rats. J. Pharm. Pharmacol. 46:1994;14-18.
50. Liu F.-Y., Shao Z., Kildsig D.O., Mitra A.K. Pulmonary delivery of free and liposomal insulin. Pharm. Res. 10:1993;228-232.
51. Komada F., Iwakawa S., Yamamato N., Sakakibara H., Okumura K. Intratracheal delivery of peptide and protein agents: absorption from solution and dry powder by rat lung. J. Pharm. Pharmacol. 83:1994;863-867.
52. Niven R.W., Whitcomb K.L., Kinstler O., Ip A.Y., Shaner L. Intratracheal instillation vs aerosol administration of rhG-CSF and PEGylated rhG-CSF. Pharm. Res. 12:1994;1143-1349.
53. Colthorpe P., Farr S.J., Smith I.J., Wyatt D., Taylor G. The influence of regional deposition on the pharmacokinetics of pulmonary delivered human growth hormone in rabbits. Pharm. Res. 12:1995;356-359.
54. Niven R.W.L., Whitcomb K.L., Woodward M., Liu J., Jornacion C. Systemic absorption and activity of recombinant consensus interferons and after intratracheal instillation and aerosol administration. Pharm. Res. 12:1995;1889-1895.
55. Colthorpe P., Farr S.J., Taylor G., Smith I.J., Wyatt D. The pharmacokinetics of pulmonary delivered insulin: a comparison of intratracheal and aerosol administration to the rabbit. Pharm. Res. 9:1992;764-768.
56. Sakr F.M. A new approach for insulin delivery via the pulmonary route: design and pharmacokinetics in non-diabetic rabbits. Int. J. Pharm. 86:1992;1-7.
57. Pillai R.S., Hughes B.L., Wolff R.K., Heisserman J.A., Dorato M.A. The effect of pulmonary-delivered insulin on blood glucose levels using two nebulizer systems. J. Aerosol Med. 9:1996;227-240.
58. Li Y., Mitra A.K. Effects of formulation variables on the pulmonary delivery of insulin. Drug Dev. Ind. Pharm. 20:1994;2017-2024.
59. Edwards D.A., Hanes J., Caponetti G., Hrkach J., Ben-Jebria A., Eskew M.L., Mintzes J., Deaver D., Lotan N., Langer R. Large porous particles for pulmonary drug delivery. Science. 276:1997;1868-1871.
60. Vanbever R., Ben-Jebria A., Mintzes J.D., Langer R., Edwards D.A. Sustained-release of insulin from insoluble inhaled particles. Proc. Control. Release Bioact. Mater. 25:1998;261-262.
61. R.K. Wolff, Safety of inhaled proteins for therapeutic use, J. Aerosol Med. (in press).
62. Low F.N., Ferrill H.W. Chronic insulin injection in five successive generations of white rats: report of gross and histological findings. Endocrinology. 29:1941;1027-1028.
63. Holt P.G., Sedgwick J.D. Suppression of IgE responses following inhalation of antigen. A natural homeostatic mechanism which limits sensitization of aeroallergens. Immunol. Today. 8:1987;14-15.